Abstract: Semi-synthetic glycopeptides that have antibacterial activity are based on modifications of a rearranged vancomycin or desmethyl-vancomycin scaffold, in particular, alkylation or acylation of the amino substituent on the amino-substituted sugar moiety on this scaffold with certain acyl groups; and/or conversion of the acid moiety on the macrocyclic ring of this scaffolds to certain substituted amides. Also provided are methods for synthesis of the compounds, pharmaceutical compositions containing the compounds, and methods of use of the compounds for the treatment and/or prophylaxis of diseases, especially bacterial infections.

Abstract: Provided are a method, system, and article of manufacture, wherein in one implementation of the method a memory buffer is allocated in a host memory by a protocol processor, wherein the host memory is comprised in a host that is coupled to a network adapter. A packet is processed initially at the network adapter to generate data for offloading to the memory buffer in the host. The generated data is offloaded by the protocol processor to the memory buffer in the host. The offloaded data is processed by the protocol processor.

Abstract: Semi-synthetic glycopeptides that have antibacterial activity are based on modifications of a rearranged vancomycin or desmethyl-vancomycin scaffold, in particular, alkylation or acylation of the amino substituent on the amino-substituted sugar moiety on this scaffold with certain acyl groups; and/or conversion of the acid moiety on the macrocyclic ring of this scaffolds to certain substituted amides. Also provided are methods for synthesis of the compounds, pharmaceutical compositions containing the compounds, and methods of use of the compounds for the treatment and/or prophylaxis of diseases, especially bacterial infections.

Abstract: The present invention discloses methods and compositions for viral inhibition, particularly inhibition of HCV and SARS. The invention also provides compositions including carbazole derivatives useful for viral inhibition.

Abstract: Machine-readable media, methods, and apparatus are described for transferring data. In some embodiments, an operating system may allocate pages to a buffer and may build a memory descriptor list that references the pages allocated to the buffer. A direct memory access (DMA) controller may process the memory descriptor list and transfer data between a buffer defined by the memory descriptor list and another location per the memory descriptor list. The DMA controller may further support data transfers that involve buffers defined by scatter gather lists and/or chained DMA descriptors built by a device driver.

Abstract: New pyrrole based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

Abstract: Semi-synthetic glycopeptides that have antibacterial activity are based on modifications of the desmethyl-vancomycin scaffold, in particular, acylation of the amino substituent on the amino-substituted sugar moiety on this scaffold with certain acyl groups; and/or conversion of the acid moiety on the macrocyclic ring of this scaffolds to certain substituted amides. In addition, compounds of the invention include desmethyl-vancomycin scaffolds on which the acid moiety on the macrocyclic ring is converted to certain substituted amides and the amino substituent on the amino-substituted sugar moiety is alkylated with certain alkyl groups. Also provided are methods for synthesis of the compounds, pharmaceutical compositions containing the compounds, and methods of use of the compounds for the treatment and/or prophylaxis of diseases, especially bacterial infections.

Abstract: New pyrrole based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.

Abstract: Semi-synthetic glycopeptides that have antibacterial activity are based on modifications of a rearranged vancomycin or desmethyl-vancomycin scaffold, in particular, alkylation or acylation of the amino substituent on the amino-substituted sugar moiety on this scaffold with certain acyl groups; and/or conversion of the acid moiety on the macrocyclic ring of this scaffolds to certain substituted amides. Also provided are methods for synthesis of the compounds, pharmaceutical compositions containing the compounds, and methods of use of the compounds for the treatment and/or prophylaxis of diseases, especially bacterial infections.

Abstract: Apparatus and method for carrying out a DMA transfer wherein an address is written into a DMA register of a DMA controller specifying a memory location within a memory device at which either the parameters for a transfer of a block of data are provided or the status of the transfer of a block of data is to be written by the DMA controller.

Abstract: Provided are a method, system, and article of manufacture, where in one embodiment of the method metadata related to a packet may be allocated in a host memory by a protocol processor, where the host memory may be comprised in a host that may be capable of being coupled to a network adapter. The metadata may be copied from the host memory to an adapter memory that may be associated with the network adapter. The copied metadata may be processed by the protocol processor.

Abstract: Briefly, in accordance with one embodiment of the invention, a system includes: a network interface unit (NIU). The network interface unit (NIU) is adapted to monitor bandwidth utilization of the network interface unit and adjust the minimum interval for the transmission of a flow control packet, based, at least in part, on the bandwidth utilization determination. Briefly, in accordance with another embodiment of the invention, an apparatus includes at least one integrated circuit includes the capability, either alone or in combination with other integrated circuits, to monitor the receive rate utilization of a network interface unit and adjust the minimum interval for the transmission of a flow control frame, based, at least in part, on the receive rate utilization determined.

Abstract: Compounds of Structure I, and salts, tautomers, stereoisomers, and mixtures thereof may be used in methods of inhibiting checkpoint kinase 1 in subjects, in methods for inducing cell cycle progression, and in methods for increasing apoptosis in cells. Such compounds may be used to prepare pharmaceutical compositions and may be used in conjunction with DNA damaging agents.

Abstract: Tetrahydrocarboline compounds, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the tetrahydrocarboline compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the tetrahydrocarboline compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases.

Abstract: Methods of treating cancer include contacting a cancer cell with 4-amino-5-fluoro-3-(5-piperazin-1-yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one, 4-amino-5-fluoro-3-[5-(4-methyl-4-oxidopiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one, tautomers thereof, pharmaceutically acceptable salts thereof, pharmaceutically acceptable salts of the tautomers thereof, or a mixture thereof.

Abstract: Briefly, in accordance with one embodiment of the invention, a system includes: a network interface unit (NIU). The network interface unit (NIU) is adapted to monitor bandwidth utilization of the netrwork interface unit and adjust the minimum interval for the transmission of a flow control packet, based, at least in part, on the bandwidth utilization determination. Briefly, in accordance with another embodiment of the invention, an apparatus includes at least one integrated circuit. The integrated circuit includes the capability, either alone or in combination with other integrated circuits, to monitor the receive rate utilization of a network interface unit and adjust the minimum interval for the transmission of a flow control frame, based, at least in part, on the receive rate utilization determined.

Abstract: Provided are a method, system, and article of manufacture, wherein in one embodiment of the method metadata related to a packet may be allocated in a host memory by a protocol processor, wherein the host memory may be comprised in a host that may be capable of being coupled to a network adapter. The metadata may be copied from the host memory to an adapter memory that may be associated with the network adapter. The copied metadata may be processed by the protocol processor.

Abstract: Briefly, in accordance with one embodiment of the invention, a method of synchronizing two ends of a bi-directional network communication path includes the following. A sequence of predetermined characters are repeatedly transmitted from an end of a bi-directional network communication path if reception is lost at that end. Synchronization or resynchronization occurs from both ends if the sequence of predetermined characters is received at the other end.

Abstract: The present invention is directed to novel immune potentiators, novel vaccine adjuvants, novel compounds and pharmaceutical compositions, novel methods for treating viral infections, including HCV, by administering the compounds, and novel methods for modulating an immune response by administering the compounds.

Abstract: Provided are a method, system, and article of manufacture, wherein in one implementation of the method a memory buffer is allocated in a host memory by a protocol processor, wherein the host memory is comprised in a host that is coupled to a network adapter. A packet is processed initially at the network adapter to generate data for offloading to the memory buffer in the host. The generated data is offloaded by the protocol processor to the memory buffer in the host. The offloaded data is processed by the protocol processor.